Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $19.68 Analyst target: $39.00 Upside: 98.17%
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.